The Conundrum of Hepatitis C Part 2: To Treat, or Not to Treat?
By Michael Bertaut, Healthcare Economist
In Part 1 of this Blog on Hepatitis C, we looked at recent advancements in treatments and their costs, as well as the studies underway to determine how widespread the disease is. We learned that millions are infected, new prescription drugs are very effective and their costs sky-high.
